Teva to Present at the 40th Annual J.P. Morgan Healthcare Conference
05 January 2022 - 05:35AM
Business Wire
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today
announced that President & CEO Kåre Schultz will present at the
virtual 40th Annual J.P. Morgan Healthcare Conference on Tuesday,
January 11, 2022. The presentation will begin at 9:45 A.M. Eastern
Time.
To access a live webcast of the presentation, visit Teva’s
Investor Relations website at http://ir.tevapharm.com.
An archived version of the webcast will be available within 24
hours after the end of the live discussion and will be accessible
for up to 30 days.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
specialty medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This document and the conference call may contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, which are based on
management’s current beliefs and expectations and are subject to
substantial risks and uncertainties, both known and unknown, that
could cause our future results, performance or achievements to
differ significantly from that expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our
ability to successfully compete in the marketplace; our substantial
indebtedness; our business and operations in general; compliance,
regulatory and litigation matters; other financial and economic
risks; and other factors discussed in our Annual Report on Form
10-K for the year ended December 31, 2020, including in the
sections captioned “Risk Factors.” Forward-looking statements speak
only as of the date on which they are made, and we assume no
obligation to update or revise any forward-looking statements or
other information contained herein, whether as a result of new
information, future events or otherwise. You are cautioned not to
put undue reliance on these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220104005903/en/
IR Contacts Ran Meir (267) 468-4475 Yael Ashman +972 (3)
914 8262 PR Contacts Kelley Dougherty (973) 832-2810 Eden
Klein +972 (3) 906 2645
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Mar 2024 to Mar 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Mar 2023 to Mar 2024